6-氟苯并[b]噻吩-2-羧酸乙酯 | 212078-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 6-氟苯并[b]噻吩-2-羧酸乙酯
• 英文名称: ethyl 6-fluorobenzo[b]thiophene-2-carboxylate
• 英文别名: 6-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester；ethyl 6-fluoro-1-benzothiophene-2-carboxylate
• CAS: 212078-68-7
• 化学式: C₁₁H₉FO₂S
• 分子量: 224.256
• InChiKey: TVDHAURTADJRSV-UHFFFAOYSA-N

物化性质

• 沸点：
  321.9±22.0 °C(Predicted)
• 密度：
  1.306±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-氟苯并[b]噻吩-2-羧酸乙酯 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 18.0h， 生成 (S)-2-(6-fluorobenzo[b]thiophene-2-carboxamido)-3-phenylpropanoic acid
  参考文献：
  名称：

  Small-Molecule Inhibitors of the TLR3/dsRNA Complex

  摘要：

  The protein-RNA interface has been regarded as "undruggable" despite its importance in many biological processes. The toll-like receptor 3 (TLR3)/double-stranded RNA (dsRNA) complex provides an exciting target for a number of infectious diseases and cancers. We describe the development of a series of small-molecule probes that were shown to be competitive inhibitors of dsRNA binding to TLR3 with high affinity and specificity. In a multitude of assays, compound 4a was profiled as a potent antagonist to TLR3 signaling and also repressed the expression of downstream signaling pathways mediated by the TLR3/dsRNA complex, including TNF-alpha and IL-1 beta.

  DOI：

  10.1021/ja111312h
• 作为产物：
  描述：

  2,4-二氟苯甲醛 、 巯基乙酸乙酯 在 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 20.0h， 以21%的产率得到6-氟苯并[b]噻吩-2-羧酸乙酯
  参考文献：
  名称：

  苯并[b]噻吩酰腙类抗多药耐药金黄色葡萄球菌的合成及生物学评价

  摘要：

  将苯并[b]噻吩核与酰基腙官能团结合，制备了三个新系列化合物，用于筛选金黄色葡萄球菌。取代的苯并[b]噻吩-2-羧酸酰肼与各种芳族或杂芳族醛的反应产生了 26 种最终产物，在芳环和苯并[b]噻吩核的 6 位上具有广泛的结构多样性。筛选导致鉴定出八个命中，包括 (E)-6-chloro-N'-(pyridin-2-ylmethylene)benzo[b]thiophene-2-carbohydrazide (II.b)，一种非细胞毒性衍生物，显示对三种金黄色葡萄球菌菌株的最低抑菌浓度为 4 µg/mL，其中分别是参考经典菌株和对甲氧西林和达托霉素耐药的两种临床分离菌株。

  DOI：

  10.3390/biom12010131

文献信息

• Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments
  申请人：NEUROVANCE, Inc.

  公开号：US20140303207A1

  公开（公告）日：2014-10-09

  The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.

  本发明提供了新型的1-杂芳基-3-氮杂双环[3.1.0]己烷化合物，以及用于制备这些化合物的相关过程和中间体，还包括使用这些化合物的组合物和方法，用于治疗和/或预防中枢神经系统（CNS）疾病，包括但不限于抑郁症和焦虑症。
• C17,20-Lyase inhibitors I. Structure-based de novo design and SAR study of C17,20-lyase inhibitors
  作者：Nobuyuki Matsunaga、Tomohiro Kaku、Fumio Itoh、Toshimasa Tanaka、Takahito Hara、Hiroshi Miki、Masahiko Iwasaki、Tetsuya Aono、Masuo Yamaoka、Masami Kusaka、Akihiro Tasaka

  DOI：10.1016/j.bmc.2004.02.007

  日期：2004.5

  Novel nonsteroidal C(17,20)-lyase inhibitors were synthesized using de novo design based on its substrate, 17 alpha-hydroxypregnenolone, and several compounds exhibited potent C(17,20)-lyase inhibition. However, in vivo activities were found to be short-lasting, and in order to improve the duration of action, a series of benzothiophene derivatives were evaluated. As a result, compounds 9h, (S)-9i,

  新型非甾体类C（17,20）-裂合酶抑制剂是基于其底物，17α-羟基孕烯醇酮使用从头设计合成的，几种化合物均表现出有效的C（17,20）-裂合酶抑制作用。然而，发现体内活性是持久的，并且为了改善作用的持续时间，评估了一系列苯并噻吩衍生物。结果，鉴定出具有纳摩尔酶抑制（IC（50）= 4-9 nM）和9e（IC（50）= 27 nM）的化合物9h，（S）-9i和9k具有强大的体内功效，延长行动时间。证明体内功效的关键结构决定因素是苯并噻吩环上的5-氟基团和4-咪唑基部分。9k和17α-羟基孕烯醇酮的叠加显示了它们的结构相似性，并使药理学结果合理化。此外，选定的化合物也被鉴定为具有20-30 nM的IC（50）值的人类酶的有效抑制剂。
• Fused ring compounds, process for producing the same and use thereof
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06420375B1

  公开（公告）日：2002-07-16

  To provide a novel compound of the formula: [wherein A1 ix a 5 or 6-membered ring which may be substituted by a group not containing a cyclic group, A2 is an aromatic ring which may be substituted, X is a divalent group, Y is a nitrogen atom or a methine group, Z is an ethenylene which may be substituted or ethynylene, R is a heterocyclic group which may be substituted, provided that 3,4-dihydro-6-[3-(1H-imidazol-1-yl)-1-propenyl]-2(1H)-quinolone and 2-[3-[5-ethyl-6-methyl-2-(benzyloxy)-3-pyridyl]-1-propenyl]benzoxazole are excluded.], or a salt thereof which has steroid C17,20-lyase inhibitory activity, and is useful for preventing and treating mammals suffering from, for example, primary cancer of malignant tumor, its metastasis and recurrence thereof.

  提供一种新颖的化合物，其化学式为： 其中A1是一个5或6成员环，可以被不含环状基团的基团取代，A2是一个芳香环，可以被取代，X是一个二价基团，Y是一个氮原子或一个亚甲基基团，Z是一个可以被取代的乙烯基或乙炔基，R是一个可以被取代的杂环基团，但不包括3,4-二氢-6-[3-(1H-咪唑-1-基)-1-丙烯基]-2(1H)-喹啉和2-[3-[5-乙基-6-甲基-2-(苄氧基)-3-吡啶基]-1-丙烯基]苯并噁唑，或其盐，具有类固醇C17,20-裂解酶抑制活性，对于预防和治疗患有原发性癌症、恶性肿瘤、其转移和复发等疾病的哺乳动物是有用的。
• Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
  申请人：Skolnick Phil

  公开号：US20090069374A1

  公开（公告）日：2009-03-12

  The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.

  本发明提供了新型的1-杂环芳基-3-氮杂双环[3.1.0]己烷化合物，以及制备这些化合物的相关工艺和中间体，以及利用这些化合物治疗和/或预防中枢神经系统（CNS）疾病的组合物和方法，包括但不限于抑郁症和焦虑症。
• 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
  申请人：NEUROVANCE, Inc.

  公开号：US09133159B2

  公开（公告）日：2015-09-15

  The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.

  该发明提供了新型的1-杂环芳基-3-氮杂双环[3.1.0]己烷，以及制备这些化合物的相关过程和中间体，以及使用这些化合物的组合物和方法，用于治疗和/或预防中枢神经系统（CNS）疾病，包括但不限于抑郁症和焦虑症。